Proton therapy developer Ion Beam Applications (IBA) posted revenue growth in the first half of 2019 (end-June 30), which it attributed to sales of its Proteus One proton therapy system and other accelerator systems.
Total group revenue for the six-month period increased by 13.8% to 102.8 million euros ($113.9 million U.S.), compared with 90.3 million euros ($100.1 million) in the first half of 2018. The company's six-month net loss decreased to 5.3 million euros ($5.8 million), compared with a net loss of 7 million euros ($7.7 million) in the same period of 2018, the company said.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&fit=crop&h=100&q=70&w=100)
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
